Log In


Company Name : Ferring Pharmaceuticals

Thursday, February 15, 2018 4:13PM IST (10:43AM GMT)


Ferring Announces 30 Million CHF Investment in New Biotech Centre in Switzerland

Ferring expands its capabilities in biologics through a new biotech centre, which will be installed at its global headquarters and manufacturing site in St Prex, Switzerland; Ferring Biotech Centre will incorporate discovery and development capabilities for monoclonal antibodies as well as manufacturing capabilities for biologics; In addition to new biologics in reproductive medicine and women’s health, fertility treatment Rekovelle® (follitropin delta) will also be manufactured at the new centre

Saint-Prex, Switzerland

Ferring Pharmaceuticals announced that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland.


Over the next three years, Ferring will invest approximately 30 million CHF in the new Ferring Biotech Centre, which will incorporate discovery and development capabilities for monoclonal antibodies as well as biologics manufacturing capabilities.


“Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core areas of reproductive medicine and women’s health, gastroenterology and urology,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “This significant investment in state-of-the art manufacturing and development technologies fits our strategy to address unmet patient needs in these areas, and will open up additional opportunities for Ferring to help people live better lives.”


In addition to the discovery, development and manufacture of new biologics, the active pharmaceutical ingredient (API) for Rekovelle® (follitropin delta), Ferring’s latest fertility treatment, will also be manufactured at the new Ferring Biotech Centre.


Earlier this year, Ferring announced a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform® to discover new human monoclonal antibodies and accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology. Together, these investments significantly expand Ferring’s growing capabilities in biologics to create innovative solutions for patients.


- Ends -


About Ferring Pharmaceuticals:


Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.


Learn more at www.ferring.com and @Ferring, or connect with us on Facebook, Instagram and LinkedIn.





Click here for Media Contact Details

Ferring Corporate Communications Team:
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)

More News from Ferring Pharmaceuticals

15/03/2018 7:05PM

Ferring Announces Positive Outcome of European Decentralised Procedure (DCP) for Testavan®, a Treatment for Men with Hypogonadism

Testavan® expands treatment options for men with hypogonadism, a condition which causes low levels of testosterone and which may adversely affect quality of life and sexual function1-3 Men treated with Testavan ...

07/03/2018 6:16PM

March of Dimes and Ferring Announce New Prematurity Research Center at Imperial College London

March of Dimes and Ferring Pharmaceuticals today announced that March of Dimes has selected Imperial College London as the first European partner to join its network of Prematurity Research Centers working to find the ...

23/02/2018 11:40AM

Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage

Excessive bleeding after childbirth (postpartum haemorrhage or PPH) is the leading direct cause of maternal mortality worldwide1 The CHAMPION trial is assessing the effectiveness and safety of heat-stable ...

Similar News

22/03/2018 6:15PM

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that final data from the pivotal Phase 2 PACE clinical trial of ICLUSIG (ponatinib) in refractory chronic myeloid leukemia (CML) or Philadelphia ...

No Image

22/03/2018 11:42AM

Eye7, AIIMS and Medanta Introduce Contoura Vision Laser Eye Surgery in Delhi-NCR

Contoura Vision Topography-Guided Laser Correction, the most advanced modality of laser vision correction, has now been introduced in India. In fact, despite the fact that Contoura Vision only received US FDA approval ...